Can a tailored antibiotic plan outsmart superbugs in african hospitals?
NCT ID NCT07820332
First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time
Summary
Researchers are studying whether a diagnostic and antibiotic stewardship algorithm can improve treatment for patients with multidrug-resistant Gram-negative bacterial bloodstream infections in Côte d'Ivoire, Guinea-Bissau and Nigeria. The study has two stages: first, they will map which resistant bacteria are present and how they respond to antibiotics; second, they will use that information to guide antibiotic choices and make newer antibiotics available. The goal is to see if this approach reduces deaths and improves clinical cure compared with usual care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A diagnosis-and-treatment algorithm that guides antibiotic choice, paired with access to newer antibiotics (meropenem, ceftazidime-avibactam, cefiderocol, and ceftazidime-avibactam plus aztreonam)
- What this could lead to
- If the algorithm works, hospitals in sub-Saharan Africa could have a practical way to choose effective antibiotics faster for patients with hard-to-treat bloodstream infections, potentially lowering deaths.
- What could go wrong
- The study is not randomized, so improvements could reflect better general care rather than the algorithm itself. Newer antibiotics may be unavailable or unaffordable outside the study, and resistance patterns can shift over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,320 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2027
An estimate. Start dates often move.
- Expected to finish
-
May 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patient with detection of a presumed multidrug-resistant Gram-negative bacterium (MDR GNB), identified by growth on MDR screening agar, in ≥1 blood culture bottle. Provision of written informed consent by the patient or the patient's parent(s)/legal representative(s). Exclusion Criteria: * Patients with negative blood culture or with detection of Gram-positive bacteria or mycobacteria or fungi in blood culture Patients with GNB in blood culture that are not resistant to third-generation cephalosporins (ceftriaxone or cefotaxim) or carbapenems (meropenem) Patients with polymicrobial infection Patients with GNB detected in blood cultures and without systemic infection signs, in whom the microbiological finding is unambiguously interpreted as contamination not necessitating antimicrobial treatment Patient already recruited for concurrent participation in other clinical studies or trials Patients with known anaphylactic reactions or severe hypersensitivity to beta-lactam antibiotics
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bloodstream infection multidrug-resistant gram-negative bacteria are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.